Auxilium Pharmaceuticals, Inc.

PharmaNewsIntelligence | March 17, 2020

Phase 1 clinical trials for a coronavirus vaccine have begun at Kaiser Permanente Washington Health Research Institute (KPWHR) has begun, according to a statement from the National Institutes of Health. The investigational vaccination, funded in part by the National Institute of Allergy and Infectious Disease, began today by administering the first immunization to a healthy adult between ages 18 and 55 years old. In total, the phase 1 clinical trial will enroll 45 adults who fit this criteria an...

Business Insights

UCB, Inc. | September 02, 2022

UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. The abstracts, accepted for poster presentation, underscore UCB's commitment to delivering innovative solutions that aim to address the unmet needs of people living with dermatological diseases. "We are proud to present new data from our expan...

PHARMA TECH

PR Newswire | January 24, 2024

ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Performance Validation, Inc. a 100% employee-owned company serving the life sciences industry since 1988, have partnered to deliver unique compliance-focused digital validation solutions for life sciences companies in the US. Performance Validation is an industry leader with over 30 years of experience in analyzing, identifying, and testing the most critical elements of the manuf...

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...